On April 1, 2024, iBio, Inc closed the transaction. The company issued 2,701,315 shares of the Company?s common stock, par value $0.001, pre-funded warrants to purchase up to 2,585,963 shares of the Common Stock at an exercise price of $0.0001 per share, and Series E Common Stock purchase warrants to purchase up to 5,287,278 shares of the Company?s Common Stock at an exercise price of $2.64 per share for gross proceeds of approximately $15,066,156.337. The company will issue securities pursuant to exemption provided under Regulation D from 8 investors.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | -2.50% | +5.41% | +42.34% |
1st Jan change | Capi. | |
---|---|---|
+42.34% | 17.22M | |
+32.89% | 700B | |
-4.64% | 358B | |
+19.35% | 330B | |
+3.60% | 287B | |
+16.23% | 236B | |
+6.73% | 202B | |
-9.28% | 197B | |
+5.19% | 161B | |
-2.62% | 157B |
- Stock Market
- Equities
- IBIO Stock
- News iBio, Inc.
- IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors